1. Home
  2. LMAT vs TVTX Comparison

LMAT vs TVTX Comparison

Compare LMAT & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LeMaitre Vascular Inc.

LMAT

LeMaitre Vascular Inc.

HOLD

Current Price

$111.81

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

HOLD

Current Price

$41.15

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LMAT
TVTX
Founded
1983
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.8B
IPO Year
2006
2013

Fundamental Metrics

Financial Performance
Metric
LMAT
TVTX
Price
$111.81
$41.15
Analyst Decision
Buy
Strong Buy
Analyst Count
5
13
Target Price
$105.80
$40.62
AVG Volume (30 Days)
143.7K
2.3M
Earning Date
05-05-2026
05-04-2026
Dividend Yield
0.87%
N/A
EPS Growth
30.57
92.89
EPS
2.52
N/A
Revenue
$249,602,000.00
N/A
Revenue This Year
$14.21
$44.76
Revenue Next Year
$8.88
$35.51
P/E Ratio
$45.48
N/A
Revenue Growth
13.53
N/A
52 Week Low
$78.01
$13.88
52 Week High
$118.01
$43.31

Technical Indicators

Market Signals
Indicator
LMAT
TVTX
Relative Strength Index (RSI) 52.51 67.07
Support Level $81.60 $32.62
Resistance Level $113.40 $42.06
Average True Range (ATR) 2.88 2.08
MACD -0.49 0.34
Stochastic Oscillator 21.35 85.49

Price Performance

Historical Comparison
LMAT
TVTX

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Share on Social Networks: